Topigen Pharmaceuticals Overview

  • Founded
  • 2000
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $7.02M
Latest Deal Amount

Topigen Pharmaceuticals General Information

Description

Developer of asthma and chronic obstructive pulmonary disorder therapeutics. The company's lead product, TPI-ASM8, is an inhaled combination of antisense oligonucleotides targeting key cytokines involved in asthmatic airway inflammation, and is in Phase II clinical trials. The company is also developing an antisense product against phosphodiesterase isoforms for the treatment of chronic obstructive pulmonary disorder therapeutics.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 4050 Molson Street
  • Suite 300
  • Montreal, Quebec H1Y 3N1
  • Canada
+1 (514) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Topigen Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 09-Feb-2010 $7.02M 0000 00.000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 15-Aug-2007 000.00 0000 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 06-Oct-2005 $24.3M $24.3M Completed Startup
1. Early Stage VC 11-Apr-2002 Completed Startup
To view Topigen Pharmaceuticals’s complete valuation and funding history, request access »

Topigen Pharmaceuticals Executive Team (5)

Name Title Board Seat Contact Info
Mark Parry-Billings Chief Executive Officer
Paolo Renzi Chief Scientific Officer & Founder
Barbara Van Oye Director, Finance
Alain Guimond Director, Preclinical Development
You’re viewing 4 of 5 executive team members. Get the full list »

Topigen Pharmaceuticals Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BDC Capital Venture Capital Minority 000 0000 000000 0
Caisse de dépôt et placement du Québec PE/Buyout Minority 000 0000 000000 0
Desjardins Capital Corporate Venture Capital Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
Lothian Pension Fund Limited Partner Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »